a positive SLN is merely a marker of systemic spread, indicating dissemination has already occurred. Heterogeneity of melanoma tumour cell based on variances in immunohistochemical patterns suggests there are biological differences in nodal tumours of malignant melanoma. At this time, there is no specific SLN cell marker known for melanoma. There have been reports of heterogeneous expression of different prognostic cell adhesion molecules, even within a single tumour, including C-C chemokine receptor 7 (CCR7), melanoma cell adhesion molecule (MCAM), and carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM-1). [16] [17] [18] [19] [20] Moreover, molecular mimicry, especially vasculogenic mimicry, is now thought to contribute to more aggressive tumour phenotypes, tumour migration, and invasion. Again, the exact molecular mechanisms and signal pathways in this process continue to be investigated. Overall, the spread of cutaneous melanoma, the heterogeneity of melanoma tumour cell markers, molecular mimicry, variations in tumour biology aggressiveness, and the fate of metastatic melanoma cells in the SLN are all poorly understood. Research to better understand the role of these and other novel biological markers in the SLNB technique and prognostication continues.
In our experience, a high proportion of patients followed at the Ottawa Regional Cancer Centre (ORCC) were anecdotally observed to develop metastatic melanoma after a primary cutaneous melanoma, despite a negative SNLB. The objective of this study was to determine the incidence of metastatic melanoma following negative SLNB at long-term follow-up.
Patients and Methods

Chart Review
A retrospective chart review was performed by a single reviewer. The charts of all patients diagnosed with a single primary melanoma between January 1999 and December 2004, who underwent lymphatic mapping with SLNB, followed at the ORCC were reviewed. Inclusion consisted of all subjects with a histologically confirmed primary cutaneous melanoma, a negative SLNB, and a minimum follow-up period of 6 months after SLNB. Follow-up was limited in some cases due to death from other causes, patient relocation, or noncompliance; these patients were excluded. Those who developed multiple primaries were also excluded.
Patient demographics and pathological features of the primary tumour were examined, including age at diagnosis, sex, location, Breslow depth, Clark level, the presence of regression, ulceration or mitoses greater than 1 per mm 2 , time of last follow-up, and death due to metastatic melanoma or other causes. Clark level was defined as a level I for tumours confined to the epidermis, II for tumours extending into the dermis, III for tumours invading into the deep reticular dermis, and IV for those invading beyond the dermis, into the subcutis or deeper. Metastases were grouped by location into skin, subcutaneous, nodal, lung, and distant as differentiated by the American Joint Committee on Cancer (AJCC) staging recommendations for melanoma of the skin. Distant metastases included those to bone, brain, and any other visceral sites reported. Nodal disease included any histologically confirmed lymph node metastases anywhere in the body and was not restricted to the SLN draining basin. Metastases at 2 or more sites were grouped into the combinations observed. All metastases were histologically confirmed on pathology by a pathologist. Approval for the study protocol and data collection was obtained from The Ottawa Hospital Research Ethics Board.
SLN Mapping Technique
Lymphoscintigraphy was performed using 4 to 6 intradermal injections of technetium-labelled sulfur colloid (Tc-99m-Sulfur Colloid) to premark the sentinel node. Prior to incision, iosulfan blue dye (Lymphazurin; Tyco Healthcare, Montréal, QC, Canada) was injected intradermally into the melanoma bed or around the previous melanoma excision site, in a clockwise pattern. Dissection was performed until the blue stain was encountered. The sentinel node was identified by taking serial dynamic 15-second images over 10 minutes, followed by 1-minute-long exposures every 5 minutes until visualisation was achieved. A high count read using the Gamma probe confirmed the site of maximal dye uptake. A single general surgeon at the time performed all SLN excisions done at The Ottawa Hospital (TOH). Sentinel nodes were reconfirmed intraoperatively with a Gamma probe, and once node dissection was complete, the remaining lymphatic bed was reexamined using the probe to ensure only contactivity remained. Postoperative lymphoscintigraphy was performed only if deemed necessary by the surgeon. Using this dual technique, sentinel nodes were detected and surgically removed for serial subsectioning and histological examination with immunised chemistry for all patients. 
Histological Processing and Examination of the SLN
The sentinel nodes were sectioned into 3-mm sections, and four to seven 3-µm slices were taken from each section. These were examined with haematoxylin and eosin (H&E) staining. If the H&E staining was negative or unequivocal, additional S100, melanoma antigen recognised by T cells 1 (MART1), and human melanoma black (HMB45) stains were performed. If no micrometastases were detected, the lymph node was reported as negative. All SLNs were examined by a pathologist.
Statistical Analysis
All patients (n = 140) were divided into 2 groups: those who developed metastatic melanoma (n = 40) vs those who did not (n = 100) within the study period. Age at diagnosis, sex, location of primary, Breslow depth, Clark level, presence of ulceration, mitoses, and regression were compared between the 2 groups using the Student t test and χ 2 test for continuous and grouped variables accordingly. Follow-up time was calculated as the time in months from initial diagnosis to the time of the last follow-up encounter at the ORCC or death, whichever came first. The time to development of metastatic disease after negative SLNB and the time to death from metastatic melanoma were also calculated in months from the time of diagnosis of the initial primary cutaneous tumour. Overall mortality from metastatic melanoma was calculated as the percentage of total patients who died from metastatic melanoma within the follow-up period. Subsequent treatment of metastatic disease was not an outcome of the study objective. Deaths within the study period due to other causes were calculated separately. Where an accurate estimation of the true false-negative rate is defined as a function of the number of false-negative patients, divided by the sum of the falsenegative and true-positive patients, whereby the quotient in multiplied by 100, the false-negative and false-omission rates could not be calculated. 21 Patients with a positive SLNB were excluded for the purpose of this study. Calculations were done using Microsoft Excel (Microsoft, Redmond, Washington) and R (The R Foundation, Lucent Technologies, Murray Hill, New Jersey) software.
Results
Patient Selection
From January 1999 to December 2004, a total of 152 patients followed at ORCC with a single primary cutaneous melanoma and a negative SLNB were identified. All had a histologically confirmed primary cutaneous melanoma. Twelve patients were excluded, as they had less than a 6-month follow-up or they developed a second primary melanoma after their negative SLNB. Thus, 140 patients met the inclusion criteria and were considered in the study. A small subset of SLNB surgeries, including 4 patients who developed metastases, was done at outside centres, and these patients were then followed at the ORCC for more than 6 months between 1999 and 2004.
Description of the Cohort
During a mean follow-up period of 63 months (range, 6-148 months), 28.6% (40/140) developed metastatic melanoma and 71.4% (100/140) did not. The mean time to diagnose a metastasis was 46.4 months (range, 5-117 months). In the subset of patients who only developed nodal metastases (11/40) , the mean time to detect metastatic melanoma was 47.7 months (range, 5-117 months). For all patients with primary cutaneous melanoma with a negative SLNB, KaplanMeier estimation was used to examine the length of time patients remained metastases free (Figure 1 ). It was found that by 21 months, 10% developed metastases, 20% by 50 months, 30% by 67 months, and 40% by 103 months.
In patients who did not develop metastatic melanoma, the mean follow-up was 65 months (range, 6-148 months). The mean age at diagnosis for this group was 54 years, comprising 52% (52/100) males and 48% (48/100) females. There was no statistical difference in sex (P = .56). The mean Breslow depth was 2.33 mm with 36% (36/100) having an intermediate thickness melanoma of greater than or equal to 2.0 mm Breslow depth, 20% (20/100) had ulceration, 43% (43/100) had mitotic figures, and 6% (6/100) had regression on histopathology (Table 2 ). Of the patients who developed metastatic melanoma, the mean age at diagnosis was 58 years (P = .22). This group was composed of 57.5% (23/40) males and 42.5% (17/40) females. On histopathology, the mean Breslow depth was 3.01 mm (P = .16), and 57.5% were greater than or equal to 2.0 mm in depth (P = .020). Furthermore, 7.5% (3/40) had regression (P = .74), 45% (18/40) had ulceration (P = .0026), and 62.5% (25/40) had mitotic figures (P = .037).
No patients in either group had a Clark level I tumour. Without metastases, 12% (12/100) had an original Clark level II tumour, 27% (27/100) Clark level III, 51% (51/100) Clark level IV, 5% (5/100) Clark level V, and 5% (5/100) could not be determined from the information in the chart. Overall, the patients who developed metastatic melanoma had higher Clark level tumours (P = .042). None of these had an original tumour with Clark level I or II, 15% (6/40) had Clark level III, 62.5% (25/40) had Clark level IV, 10% (4/40) had Clark level V, and 12.5% (5/40) were unknown (Table 2) .
Finally, 22.5% (9/40) who developed metastases had a tumour thickness greater than 4.0 mm, whereas only 12% (12/100) of patients without metastases had a tumour thickness greater than 4.0 mm. Considering only primary melanomas with a depth of less than 4.0 mm, the metastatic rate is only 22.1% compared with 28.6% for all Breslow depth tumours included in this study.
Primary Tumour Sites and Patterns of Metastases
There was no statistical difference (P = .22) in primary location between the metastases and metastases-free groups (Table 2 ). In 60% (24/40), detectable metastases were observed in 1 location only (Table 3 ). In the remaining 40% (16/40), metastases were observed in multiple locations. Metastatic melanoma was noted in 1 patient in or around the excision scar. The largest proportion of metastases (11/40) occurred in lymph node(s) only, of which only a small portion (3/11) were observed following a primary melanoma of the head and neck. Nodal melanomas were not restricted to the SLN draining basin. Additional nodal metastases were observed in conjunction with 1 or more other metastatic locations in another 20% (8/40) of patients. A high proportion of metastases (7/40) also occurred in distant locations with no detectable skin, subcutaneous, or nodal involvement. 
Discussion
This study describes the patterns of metastatic melanoma among a consecutive group of patients with melanoma at a single Canadian institution. The ORCC is the only tertiary cancer referral centre serving the greater Ottawa area.
Incidence of metastatic melanoma after negative SLNB at our centre is higher than the upper limit previously reported at other centres (Table 1) . At the ORCC, 28.6% of all patients with a primary cutaneous melanoma developed metastatic melanoma following a negative SLNB at a mean follow-up of greater than 5 years. Breslow depth greater than 2.0 mm, Clark level, ulceration, and mitoses were statistically significant for the development of metastatic disease. Several reasons have been proposed in the literature regarding the prognostic challenges surrounding the use of SLNB in melanoma. Previously described postulations for SLNB failure include lymphatic disruption and obstruction, multiple drainage basins, misinterpretation of the visualisation or identification techniques, and pathology failure. 8 In addition to a missed positive SLNB, risk is further modified by a host of subsidiary factors, including Breslow depth, followed by age greater than 50 years, male sex, Clark level, the presence of ulceration, mitoses, and location on the head and neck or upper extremity. [22] [23] [24] [25] [26] [27] [28] Molecular mimicry, although not well understand, may further modify recurrence risk. Missed nodal metastases at the time of SLNB portend worse survival outcomes. 11 These patients typically become symptomatic slowly over time, while the metastatic disease grows and spread. 13 In the Multicenter Selective Lymphadenectomy Trial 1 (MSLT-1), 2 of every 3 patients who developed metastatic malignant melanoma following negative SLNB died. 9 In our patients, nodal metastatic malignant melanoma (11/40) was not detected for nearly 4 years (mean, 46.4 months; range, 5-117 months). It is unlikely for undetected nodal melanoma to remain indolent for 4 years, and thus SLNBs erroneously reported as negative would not explain our findings. Rather, metastatic melanoma following negative SLNB is more likely a result of the complex, unpredictable, and aggressive tumour biology of malignant melanoma. For nodular melanoma, the reported metastatic rate is up to 29.7% and as high as 43.1% if ulceration is present. 23 In our study, both Breslow depth greater than or equal to 2 mm and ulceration were statistically significant. When melanomas greater than 4.0 mm were excluded, only 22.1% of patients developed metastatic melanoma, suggesting a more aggressive and unpredictable malignant behaviour for deeper tumours. Breslow depth greater than 4.0 mm is known to portend a worse prognosis. 29, 30 The American Society of Clinical Oncology (ASCO) recommends SLNB for staging and regional disease control and not solely for prognostication in such thick melanomas. 31 The development of metastatic melanoma following node-negative patients in our centre is multifactorial. Our follow-up period (mean, 5.3 years; range, 0.5-12.3 years) is greater than many previously reported studies (Table 1) . We observed that on average, the time to detect a metastasis after primary diagnosis was nearly 4 years. Studies with a shorter follow-up period would not have captured this outcome.
A high number (11/40) of metastases were observed in lymph node(s) alone; thus, in-transit or distant metastases not detectable via SLNB and, although unlikely, failure of the SLNB procedure should be considered and discussed. All SLNBs were reported as negative by an experienced surgeon, using the dual approach of preoperative lymphoscintigraphy and intraoperative blue dye injection in conjunction with a handheld Gamma probe. This dual approach has been reported to identify a sentinel node with greater than 96% accuracy. 32 In the primary head and neck group, only a small number (3/11) developed nodal metastases. This was not found to be statistically significant despite the complex draining basins found in the head and neck region. We acknowledge that this group is small, however, and that it did trend more towards significance than other primary location groups. This is not surprising based on what we already know about prognosis in the head and neck. The highest proportion (13/40) of metastases occurred in the lung and/or another distant location, however, suggesting that SLNB does not capture all in-transit metastases. Moreover, 40% (16/40) of metastases observed involved multiple locations, half of which (8/16) did not involve any detectable lymph nodes. In 1 patient in whom an error in technique was suspected as a metastasis that developed in or near the skin of the original scar, review of the original excisional pathology indicated only scar remained with no remaining melanoma. Although failures in the surgery and nuclear medicine techniques cannot be entirely excluded, they are unlikely. Again, malignant melanoma is a dynamic disease. A SLNB at a single fixed point in time simply cannot detect all metastases that arise and evolve over time. This is not necessarily a function of the technique. Given the time lag of nearly 4 years to metastatic disease, a negative SLNB around the diagnosis of a primary cutaneous melanoma does not adequately represent the long-term behaviour of malignant melanoma.
Despite negative SLNB, long-term outcomes can be devastating. Excluding skin, subcutaneous nodules, and lymph nodes, 60% (24/40) of patients developed metastases to the lung, other distant locations, or in combination with these sites. The mean time to death from detection of metastatic melanoma was only 13.2 months (range, 1-64 months). This has important implications for long-term surveillance, as skin and lymph node exams by a dermatologist alone would not necessarily detect distant and lung metastases unless the patient was symptomatic from tumour burden. A multidisciplinary long-term follow-up approach would be best for patients. In total, 62.5% of patients with metastatic melanoma died within the study period. The overall mortality due to metastatic melanoma following negative SLNB was 18% at 63 months.
Distant metastatic melanoma is one of the most feared and lethal outcomes in patients with melanoma. One-year survival ranges between 33% and 53%. 8 Survival in men (75%) at 5 years has been observed to be less than in women (85%). 1 In our study, there was no statistical difference between males and females. Distant metastases have been correlated with BRAF mutated status, and NRAS mutated status has independently been observed as a poor prognostic marker in molecular tumour studies. [33] [34] [35] [36] We observed a curtailed prognosis over time following negative SLNB, potentially giving patients and physicians a false sense of security. Given the delay of years we observed before metastases were detected (mean, 3.9 years; range, 0.42-9.75 years), long-term surveillance by both a dermatologist and oncologist, if not lifelong, could help detect metastases as early as possible. As novel targeted therapies continue to be developed and studied in patients, our understanding of treatment and long-term survival outcomes in metastatic melanoma will evolve. At the time of this study, most targeted therapies for metastatic melanoma treatment were not available. Although management of metastases was not studied, note that anecdotally many patients declined active treatment of metastatic disease due to the advanced stage at the time of diagnosis.
To summarise, the high rate of metastatic melanoma after negative SLNB at the ORCC is likely multifactorial. The long follow-up period (mean, 5.3 years; range, 0.5-12.3 years), high proportion of melanomas greater than 4.0 mm (9/40), and mean overall patient population age greater than 50 years are all probable factors. Since the ORCC is the largest tertiary cancer centre in the area, there may be an element of referral bias for more complicated or aggressive phenotypes. Moreover, metastatic and poor prognostic molecular tumour differences detectable only by gene expression profiling (GEP), such as BRAF and NRAS mutations, may be overrepresented in our patient population, contributing to the high number of distant metastases and mortality observed. In keeping with the literature, the presence of ulceration, mitoses, Breslow thickness greater than or equal to 2 mm, and Clark level of the original primary cutaneous melanoma were all statistically significant for the development of metastatic disease in our cohort. Regression, location of primary, age, and sex did not appear to play a significant role between the 2 groups, however.
Two follow-up studies are currently under way at the ORCC to exclude missed nodal metastases at the time of SLNB and to identify relevant differences in gene expression that could help risk stratify patients. The first study involves pathological reexamination of all SLNs of patients who developed metastatic disease to ensure nodal metastases were not missed at the time of SLNB. The second study involves molecular characterisation of the primary cutaneous melanomas by GEP (nCounter; Nanostring Technologies, Inc., Seattle, Washington) to improve prognostication using a 28-gene signature.
We acknowledge that these findings are of a small, singleinstitution, retrospective observational study with no control subjects, collected between 1999 and 2004. Improvements and changes to the SLNB technique and new adjuvant targeted and immunotherapies have been developed since the follow-up period of this study, which have since changed patient outcomes. Further studies are still needed to better determine the survival outcomes in patients treated with these novel therapies. A similar long-term study at a different tertiary centre comparable in size would provide a useful cross-reference for our findings.
In conclusion, these high rates of metastatic melanoma at long-term follow-up suggest that long-term prognosis may be more guarded than previously thought in SLNB-negative patients with a primary cutaneous melanoma. Alone, a negative SLNB may give patients and clinicians a false sense of security as disease progression and mortality appear to be increased at long-term follow-up. Additional prognostic markers and more sensitive techniques are needed to better stratify patients into high-and low-risk groups for metastatic disease. Further consideration of prognostic guidelines, posttreatment surveillance, and the role for adjuvant targeted and immunotherapies in node-negative patients with other highrisk features may be warranted.
